GlassScriptPhysician profile
Paul A Sanchez
NPI 1811106685
$7,948.68
in general payments reported to CMS, 2019-2025
29 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $364 · 2021: $1,063 · 2022: $1,139 · 2023: $790 · 2024: $1,563 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,366.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,129.68 | 2019-2025 | Clareon, Unity, Hydrus Microstent |
| Abbvie INC. | $866.38 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $559.09 | 2020-2025 | Cequa, Xelpros |
| Allergan, INC. | $487.62 | 2019-2021 | |
| Glaukos Corporation | $467.76 | 2021-2025 | Idosetr |
| Rxsight INC | $440.80 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $399.93 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $209.06 | 2022-2025 | Xiidra, Miebo, Envista Envy Iol |
| Johnson & Johnson Surgical Vision, INC. | $179.28 | 2020-2025 | Tecnis Simplicity, Veritas Vision System |
| Tarsus Pharmaceuticals, INC. | $160.21 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $117.78 | 2021 | |
| Lensar, INC. | $116.15 | 2025 | Lensar Laser System |
| Seagen INC. | $99.95 | 2022 | |
| Ivantis, INC | $95.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $84.94 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $80.16 | 2025 | Vevye, Iheezo |
| Horizon Therapeutics Plc | $77.04 | 2023 | Tepezza |
| Shire North American Group INC | $64.86 | 2019 | |
| Oyster Point Pharma, INC. | $51.85 | 2023-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $49.13 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $43.47 | 2020 | |
| New World Medical,INC. | $42.64 | 2024-2025 | Clearpath, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.42 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $19.96 | 2019 | |
| Eyevance Pharmaceuticals LLC | $18.21 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $17.26 | 2021 | |
| Amgen INC. | $16.52 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $14.59 | 2022 | |
| Biotissue Holdings INC. | $13.89 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.